PharmaShots | Incisive News in 3 Shots

Subscribe Now

No EGFR

Genentech's Tecentriq Receives FDA Approval a Combination Therapy- for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations

Genentech's Tecentriq Receives FDA Approval a Combination Therapy- for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations

December 7, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us